TearAct Technology consists of resin microparticle-complexed drug in a suspension form to improve the dosing frequency from TID to QD. The conversion of a solution product to a drug-resin complex suspension product prolongs the release of drug likely reducing the immediate exposure to drug and providing a slow, consistent, and sustained exposure.

Key Features

• Fine resin particles act as a template on which the drug particle is adsorbed
• Drug-resin clusters disintegrate into individual drug bound resin particles due to eye blink shear
• Drug-resin complex suspension provides a slow, consistent, and sustained exposure

Key Benefits

• Controlled and maximal availability of drug to ocular surface
• Reduces immediate exposure of drug
• Free of gel forming polymers